loobobilly News: FDA Grants Experimental Coronavirus Drug Benefits For Rare Disease Treatments

FDA Grants Experimental Coronavirus Drug Benefits For Rare Disease Treatments Gilead Science's remdesivir, an antiviral medicine being tested for treatment of COVID-19, would get a seven-year monopoly if approved by the Food and Drug Administration. Gilead Science's remdesivir, an antiviral medicine being tested for treatment of COVID-19, would get a seven-year monopoly if approved by the Food and Drug Administration. Business
Gilead Science's remdesivir, an antiviral medicine being tested for treatment of COVID-19, would get a seven-year monopoly if approved by the Food and Drug Administration.

Read more on NPR